The International Parkinson and Movement Disorder Society (MDS) gathers thousands of clinicians, researchers, trainees, and industry supporters to discuss the diagnosis and treatment of movement disorders on an annual basis.
Understanding the Therapeutic Potential of GT-02287 in GBA-Parkinson Disease
October 14th 2024Jonas Hannestad, MD, PhD, chief medical officer at Gain Therapeutics, provided clinical perspective on promising data from a phase 1 first-in-human study of GT-02287, an investigational therapy for Parkinson disease with or without a GBA1 mutation.
Mechanism of Stem Cell Therapy Bemdaneprocel for Parkinson Disease: Amit Rakhit, MD
October 9th 2024The chief medical officer and chief development officer at BlueRock Therapeutics discussed the promise behind bemdaneprocel and its unique mechanism of action relative to other Parkinson disease treatments. [WATCH TIME: 3 minutes]
Continued Progress in Phase 1 Study of Antisense Oligonucleotide ION464 in MSA
October 2nd 2024ION464 is designed to inhibit the production of the alpha-synuclein protein, aiming to reduce the accumulation of this protein in the brain, which is believed to be a key factor driving neurodegeneration in MSA and Parkinson disease.
Potential Promise Behind ATH434 for Multiple System Atrophy: Daniel Claassen, MD, MS
October 2nd 2024The director of the Huntington’s Disease Clinic at Vanderbilt University Medical Center gave commentary on the unique development of ATH434, its ability to target iron accumulation, and how it may slow disease progression in multiple system atrophy. [WATCH TIME: 3 minutes]
Extended-Release Amantadine Shows Reduction in Dyskinesia Severity for Parkinson Disease
October 1st 2024Amantadine extended-release capsules, approved for levodopa-related dyskinesia and OFF episodes in Parkinson disease, offer high amantadine concentrations that peak in the time of first morning levodopa dose.
Positive 24-Month Data of Cell Therapy Bemdaneprocel in Parkinson Disease: Amit Rakhit, MD
October 1st 2024The chief medical officer and chief development officer at BlueRock Therapeutics provided perspective on newly presented data investigating a cell therapy for patients with Parkinson disease. [WATCH TIME: 4 minutes]
Mechanism Behind Ulixacaltamide to Treat Essential Tremor: Marcio Souza
October 1st 2024The president and chief executive officer at Praxis Precision Medicine provided clinical insight on the promising build of ulixacaltamide, an investigational, selective agent in development for essential tremor. [WATCH TIME: 3 minutes]
Nocturnal and Morning Akinesia Still Prevalent After Nighttime Add-On Parkinson Medications
September 30th 2024In a post hoc analysis of the COSMOS study, 24-hour LCIG infusion led to a reduction in nocturnal and morning akinesia, though many patients continued to rely on nighttime add-on medications.
Potential of Device-Assisted Therapy for Advanced-Stage Parkinson Disease: David Devos, MD, PhD
September 29th 2024The neuropharmacologist at the University of Lille, in France, provided commentary on promising results from the phase 1/2 DIVE-I trial assessing the safety and efficacy of a device-assisted therapy in Parkinson disease. [WATCH TIME: 6 minutes]
The Future of Parkinson Disease Treatment With Innovative Wearable Devices: Alistair Mackett, MD
September 24th 2023The movement disorder specialist at Cambridge University Hospitals NHS Foundation Trust discussed the rise of wearable technology for managing Parkinson disease to potentially empower patients and monitor the disease at early stages. [WATCH TIME: 4 minutes]
Neurobiological Insights Into Gait and Balance Control in Parkinson Disease
September 5th 2023Nicolaas Bohnen, MD, PhD, professor of radiology and neurology at the University of Michigan, discussed the main takeaways from his keynote lecture on posture and gait in Parkinson disease presented at the 2023 MDS Congress.
Phase 3 KINECT-4 Findings Show Valbenazine Decreases Tardive Dyskinesia Severity
September 4th 2023On average, clinician-rated TD severity, measured by AIMS, and patient-reported assessment of the physical, social and emotional impact of TD, measured by TDIS, decreased with one-capsule, once-daily valbenazine over 48 weeks.
Levodopa as Initial Parkinson Treatment Shows Best Long-Term Prognostic Outcome for Quality of Life
September 1st 2023When compared with levodopa-sparing agents, treatment levodopa alone resulted in significantly better patient-rated Parkinson’s Disease Questionnaire activities of daily living and summary index scores.
Machine Learning Algorithm Accurately Diagnoses Parkinsonian Syndromes, Study Shows
September 1st 2023Parkinsonian syndromes, including multiple systems atrophy and progressive supranuclear palsy, have similar symptoms to Parkinson disease but are more distinct and each have corresponding therapies that are available for them.
Machine Learning Algorithm Shows Ability to Distinguish Tic From NonTic Movements
August 31st 2023Despite the challenge of distinguishing tics from extra movements, machine learning technology could potentially help researchers with reducing time spent analyzing video recordings of patients with tic disorders.